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In this multi-center, naturalistic study, the effectiveness
of naltrexone maintenance combined with the Community
Reinforcement Approach (CRA) was investigated in detox-
ified, opioid-dependent patients (N¼272). Patients were
recruited from methadone maintenance programs. With
intention-to-treat analysis, 10 months of treatment yielded
abstinence rates of 28% and 32% at 10 and 16 months
after detoxification. The cumulative abstinence rate at
16 months was 24%. Quality of life, craving, general psy-
chopathology, use of other psychoactive substances, and
addiction severity of the abstinent group significantly
improved when compared to the relapsed group. This
abstinence-oriented approach appears to be a feasible goal,
and remains an important option next to long-term
methadone maintenance in the management of opioid
dependence. (Am J Addict 2007;16:124–130)
INTRODUCTION
An estimated 25,000 heroin-dependent patients live in
the Netherlands (16,000,000 inhabitants). About 75% of
these addicts are served by addiction treatment centers,
particularly by means of methadone maintenance treat-
ment. About 4,500 of the opioid-dependent patients are
involved in drug-free treatment. Interventions directed
at abstinence are regarded as problematic in terms of
high drop-out and high relapse rates and prove to be
effective only in a minority of motivated patients under
stable living conditions with adequate social support.1
Given the difficulty of achieving sustained abstinence,2
there is a tendency to focus on stabilization and harm
minimization.3
Recent developments in the treatment of opioid-
dependent patients aiming at abstinence are promising.
In general, detoxification in opioid-dependent patients
is not a substitute for treatment but is regarded as the
first prominent component in a comprehensive treatment
strategy.4 Detoxification strategies based on antagonist-
induced withdrawal seem to be associated with higher
initial abstinence rates and with a guaranteed start of nal-
trexone maintenance treatment.5 Naltrexone blocks the
euphoria induced by opioids and prevents the incentive
property of sustained use. Studies on naltrexone mainte-
nance show a clear effect in highly educated and socially
well-integrated groups.6 Pharmacotherapy of opioid
addiction is more effective in combination with behav-
ioral and psychosocial approaches,7,8 although innova-
tive approaches to encourage medication adherence are
needed.9 In the Community Reinforcement Approach
(CRA), adherence to medication can explicitly be stimu-
lated. CRA regards behavior as modifiable by positive
reinforcement from the individual’s real-life community
context.10 In general, there is evidence for the efficacy
of CRA, with or without medication, in various substance-
related disorders, including alcohol, cocaine, and heroin.11
The objectives of this study were to determine whether
such a comprehensive approach results in high, long-term
abstinence rates after successful detoxification in opioid-
dependent patients and whether continuously abstinent
patients do better than relapsing patients in other
domains.
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METHODS
Study Design and Setting
From four addiction treatment centers in the
Netherlands (Novadic, Jellinek, Parnassia, and Kentron),
296 participants were recruited for this study. This is
about 9% of the population in treatment concerning
opioid dependence in these centers. Twenty-four did not
meet the inclusion criteria (n¼5) or refused to participate
(n¼19). The 272 participants were randomized and allo-
cated to two treatment arms. One treatment consisted of
rapid detoxification without anesthesia carried out on an
addiction center clinic. The comparative treatment, rapid
detoxification under general anesthesia, comprised a com-
plete detoxification in a hospital setting followed by the
monitoring of the patients at an addiction center clinic.
Rapid detoxification under general anesthesia had no
more effect than rapid detoxification without anesthe-
sia.12 Both detoxification techniques demonstrate a clear
reduction of relapse among patients in the withdrawal
process. Consequently, both groups were collapsed in
further analyses following a naturalistic design. After this
standardized inpatient detoxification program of one
week, all 272 patients started treatment with naltrexone
maintenance and CRA in an outpatient condition.
Follow-up was conducted at 1, 10, and 16 months after
detoxification.
Participants
All patients were recruited from the standard metha-
done maintenance programs on a voluntary basis. They
had attended these programs for at least a year, were at
least 18 years old, and met the diagnostic criteria for
opioid dependence according to Diagnostic and Statistical
Manual of Mental Disorders.13 They underwent several
unsuccessful attempts to become abstinent, expressed
their clear wish to become abstinent, and were familiar
with the Dutch language. Exclusion criteria were severe
somatic diseases or psychiatric disorders, pregnancy,
AIDS, doubts about the patient’s willingness to coop-
erate, and contraindications regarding general anesthesia.
Patients were not excluded for a dependence on other
drugs or drug abuse. However, because of the unpredict-
able effects of cocaine on the cardiovascular system dur-
ing anesthesia, treatment was postponed for 48 hours if
a patient had used cocaine shortly before detoxification.
Treatment
The CRA protocol encompassed twenty-three sessions.
Physicians and psychosocial therapists administered the
sessions. This protocol was tailored on the CRA manual
of Meyers and Smith.10 Each of the four treatment sites
facilitated a staff to the CRA program that consisted of
two physicians and two or three psychosocial therapists,
depending on the number of included patients, which var-
ied between 36–86. With respect to the duration of this
study (patients were recruited from November 1999 to
July 2001), each therapist had a caseload of 10–15
patients. Experienced addiction counselors (social work-
ers and master’s-level psychologists) or master’s-level psy-
chology students delivered the psychosocial therapy.
Experienced physicians delivered medical support and
administered naltrexone. Treatment integrity regarding
the philosophy of CRA was warranted by a two-day
training course prior to the beginning of the study for
all CRA physicians and therapists. The CRA methodol-
ogy was guarded on the basis of notes and stored in files.
Furthermore, the second author conducted monthly
supervision during the study on each treatment site. For
both series, a detailed protocol was available for the treat-
ment by the physician and the psychosocial worker.14
In 10 psychosocial sessions, the lifestyle of the patient
was assessed and discussed. In these sessions, attention
was paid to drug-refusing behavior, relational issues,
social counseling, recreational counseling, vocational
counseling, problem solving abilities, training in social
skills, and craving management. All patients were referred
to the first psychosocial session, which was prior to detox-
ification. The second psychosocial session was admini-
stered at discharge of the detoxification procedure. With
a frequency of two monthly sessions, the next two ses-
sions were planned. Sessions 5 to 8 were attended
monthly, session 9 had an interval of two months, and
session 10 had an interval of three months. Each treat-
ment session lasted about 60 minutes.
In 13 sessions, a physician administered and monitored
compliance with naltrexone (50mg dd), addictive behav-
iors, craving, and the occurrence of adverse events. The
first four physician’ sessions were planned prior and dur-
ing the detoxification process. Session five was adminis-
tered one week after discharge. Sessions 6–7, 8, and 9–13
were planned after 2, 3, and 6 weeks, respectively. Each
session lasted about 20 minutes. Subjects had to be
accompanied by a non-drug-using coach during treat-
ment, such as a partner, spouse or good friend, who spe-
cifically assisted the patient with taking naltrexone.
Assessments
Independent research assistants assessed participants
at baseline and during follow-up. The primary outcome
measure was defined as self-report of no heroin and=or
methadone use in the last 30 days, as verified by urine
analysis for opioids at follow-up. The Cumulative Absti-
nence Duration (CAD) was defined as the period starting
after detoxification until the first use of opioids. At base-
line and at 16 months, the European version of the Addic-
tion Severity Index15 was used to assess the severity of
seven areas of functioning: medical, employment, alcohol,
substances, legal, family=social, and psychiatric. At all
assessment points, health domains were measured with
the SF-36.16 The health-related quality of life, based on
societal preference values (index) and from the patient
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perspective (visual analogue scale, VAS), was measured
with the EuroQol-5D.17 The use of other psychoactive
substances and addiction severity was measured with
the EuropASI. and urine analyses. Craving was measured
with a VAS and general psychopathology with the Symp-
tom Checklist-90.18
Data Management and Statistical Methods
An intention-to-treat analysis was performed. To test
differences for continuous variables, the general linear
model with repeated measures was conducted on contin-
uous variables with baseline levels as a covariate. Missing
data considering continuous variables were systematically
replaced through analysis provided by the expectation
maximization (EM) imputation algorithm. Chi-square
tests were applied for dichotomous outcomes and the
independent t-test for continuous outcomes. For all sta-
tistical analyses, SPSS version 11.5 was used.
RESULTS
After one, ten, and sixteen-month follow-up, data were
available for 78, 74, and 86% of the study population.
Table 1 shows the details of the patient population at
inclusion. Participants attended an average of 6.6 sessions
(SD¼3.8) from a physician, received approximately two
and one-half months naltrexone, and attended 4.3
(SD¼2.7) sessions of psychosocial CRA therapy.
Figure 1 shows the point prevalence of abstinence and
the CAD slope. After a one-month follow-up, 46% of the
patients were abstinent for opioids. After 10 and 16
months of follow-up, the point prevalence was 28% and
32%, respectively. The cumulative abstinence duration
(CAD) shows a decline in abstinence rates. After 10 and
16 months, 27% and 24% were continuously abstinent,
respectively.
Table 2 shows the changes over time for the secondary
outcome measures. There was a slight improvement in the
general health perception of the SF-36 during the follow-
up periods (F¼9.67, p < .001). The EuroQol-5D index
showed a significant beneficial effect during follow-up
(F¼9.05, p < .001). An overall improvement during
follow-up was also observed for the EuroQol VAS
(F¼8.48, p < .001). The ASI severity scores showed a sig-
nificant improvement on all domains except for physical
health (see Table 2). In respect to craving, Table 2 shows
a minor but statistically significant improvement on the
VAS during the follow-up period (F¼27.0, p < .001).
There was a difference between the VAS at intake and
month 1 (p < .001). Mental health, as measured by the
sum score of the SCL-90, showed a significant improve-
ment over time (F¼9.90, p < .001). All participants had
declined in the number of substance-using days during
the most recent 30 days, compared to baseline levels
(see Table 3).
There were no significant differences in baseline
characteristics between the continuously abstinent and
the relapsing group (see Table 4). Table 5 shows the
TABLE 1. Baseline characteristics of the 272 patients
Mean baseline
(SD)
Age (years) 35.9 (6.4)
Male (%) 82.0
Ethnic Dutch (%) 82.9
Employment (%)
Fully employed 50.2
Part-time employed 10.8
Unemployed 39.0
Marital status (%)
Single 70
Married 14
Divorced=widowed 16
Education (%)
Lower 70.8
Secondary 20.4
Higher 8.8
Regular drug use (years)
Heroin 12.1 (5.9)
Methadone 7.4 (5.7)
Age at first heroin use 20.8 (5.1)
Age at first methadone use 24.1 (7.2)
Number of previous detoxifications 7.9 (8.0)
EuropASI severity scores (0–9)
Physical health 1.2 (1.5)
Work, education, and income 2.2 (2.3)
Alcohol .9 (1.7)
Drugs 6.2 (1.1)
Justice=police 1.6 (1.9)
Family=social relations 2.7 (1.8)
Psych=emotional problems 2.1 (1.9)
Gambling .1 (.6)
Note: Figures are means, standard deviations, and percentages.
FIGURE 1. Point Prevalence and Cumulative Abstinence
Duration (CAD) in Opioid-Dependent Patients at 1, 10, and 16
Months Post-Detoxification
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comparison of the secondary outcomes between abstinent
and non-abstinent patients at 16-month follow-up. Com-
pared with the non-abstinent patients, the abstinent
patients had a better health-related quality of life, lower
severity scores on the EuropASI (except for alcohol score),
lower levels of craving, and lower general psychopathol-
ogy. The opioid-abstinent group used on significantly
fewer days cocaine (1.9 versus 6.3; p< .01) days and benzo-
diazepines (3.6 versus 7.0; p< .01) compared with the
relapsed patients.
DISCUSSION
This study explored the long-term outcome of opioid
antagonist-induced withdrawal in opioid-dependent
patients, followed by a comprehensive treatment in which
naltrexone maintenance was combined with the Commu-
nity Reinforcement Approach. Twenty-four percent of
participants were persistently abstinent over a 16-month
follow-up period.
These positive results can be attributed to the use of
the opioid antagonist-precipitated withdrawal techniques,
which facilitate the likelihood of successful induction into
maintenance naltrexone treatment.19,20
The results are in line with the contemporary literature
that demonstrates the value of integrating pharmacologi-
cal agents and cognitive behavioral-oriented therapies
that have been widely promulgated to achieve and main-
tain long-term abstinence in opioid abuse or to prevent
relapse.8,9,21
The degree of success is much higher than that which
could be expected from regular treatment approaches,
such as methadone tapering.2 Most studies have reported
upon follow-up periods ranging from one week to one
month.22 More recent reviews suggest that it may not
be possible to draw conclusions concerning the long-term
effectiveness or cost-effectiveness of withdrawal induced
TABLE 2. Secondary outcome measures in detoxified opioid-dependent patients
Baseline Month 1 Month 10 Month 16 p
Health perception
General health perception SF-36 (range 0–100) 57.4 (20.1)a 63.9 (22.0)b 65.4 (22.0)b 61.9 (22.8)b < .001
Quality of life
EuroQol Index (range 0–1) .74 (.23)a .72 (.25)b .76 (.21)a .76 (.22)a < .001
EuroQol VAS (range 0–100) 68.6 (17.7)a 73.6 (18.6)b 74.4 (18.3)b 74.1 (18.7)b < .001
EuropASI severity scores (range 0–9)
Physical health 1.1 (1.4) 1.0 (1.6) .619
Work, education, income 2.2 (2.3) 1.5 (2.2) < .001
Alcohol 0.9 (1.7) 0.5 (1.3) .002
Drugs 6.3 (1.0) 3.0 (2.4) < .001
Justice=police 1.6 (1.9) .7 (1.6) < .001
Family=social relations 2.8 (1.8) 1.1 (1.7) < .001
Psych=emotional problems 2.1 (1.9) 1.7 (2.1) .021
Craving
VAS 22.9 (26.5)a 7.8 (16.8)b 21.7 (30.6)a 22.1 (30.1)a < .001
SCL-90
Total score (range 90–450) 154.9 (49.5)a 139.7 (43.4)b 140.2 (50.3)b 137.4 (49.5)b < .001
Note. Figures are means and standard deviations. Means with different superscripts differ in pair-wise comparisons (SIDAK) at p < .05.
TABLE 3. Substances used in the past 30 days, according to ASI self-report
Substance Baseline Month 1 Month 10 Month 16 F p
Alcohol 6.3 (10.3) 6.0 (8.1) 6.5 (9.1) 6.9 (9.4) 0.42 .74
Heroin 18.4a (12.1) 3.0b (7.5) 8.3c (12.0) 10.3c (13.0) 53.88 .00
Methadone 22.9a (11.0) 2.9b (8.1) 8.2c (12.5) 10.6c (13.4) 75.73 .00
Opiates (other) 0.1 (1.7) 0.1 (.4) 0.4 (3.1) 0.3 (2.1) 0.79 .50
Medicines 6.0 (11.1) 8.4a (11.7) 5.2b (10.1) 5.7b (10.7) 4.40 .01
Cocaine 4.1 (7.4) 2.3 (5.8) 3.5 (7.7) 4.53 (8.8) 0.83 .48
Amphetamines .1 (.4) .0 (.2) .0 (.2) .0 (.0) 1.72 .16
Cannabis 7.5 (11.6) 6.8 (1.6) 7.8 (11.7) 8.5 (12.4) 0.65 .58
41 substance 18.1a (11.9) 4.9b (9.0) 8.7b (13.2) 10.7b (12.6) 39.26 .00
Note. Means with different superscripts differ in pair-wise comparisons (SIDAK) at p < .05. Figures are means and standard deviations.
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by opioid antagonists with minimal or heavy sedation or
anaesthesia.5,23 Several recent studies report on long-term
outcome, yielding (continuous) abstinence rates ranging
from 13 to 80%.24–32 It is impossible to draw general con-
clusions from these reports because of the wide variation
in study design, objectives, data assessment, sample size,
variety in populations, and treatment modalities.
The patients had to bring in a concerned significant
other and were characterized by relatively moderate ASI
severity scores, especially when compared to treatment-
resistant heroin-dependent patients who insufficiently
benefit form methadone maintenance treatment.33 These
ASI severity scores (n¼346) scores were 3.35 (2.26) for
physical health; 4.48 (1.70) for work, education, and
income; 1.84 (2.06) for alcohol; 6.11 (.94) for drugs;
4.39 (1.91) for justice and police; 3.60 (1.91) for family
and social relations; and 3.54 (3.00) for psychiatric and
emotional problems (personal communication, Peter
Blanken & Wim van den Brink, 26 January 2006). These
scores are up to two times higher than our patient group.
It has been shown that naltrexone may be an efficacious
adjuvant, especially for (highly) motivated patients who
fear the severe consequences of not stopping taking
opioids. Such patients may include health care profes-
sionals who may be dismissed or parolees who may be
returned to prison.6 Although the population in this study
comprised a regular group of patients in a methadone
maintenance program who were mostly single and had a
low educational level and fifty percent unemployment
rate, selection bias cannot be ruled out.
It is noteworthy that abstinence was associated with an
improvement in health. Those who did not relapse
showed improvements in addictive behaviors, craving,
health, and health-related quality of life. Even those
who were only temporarily abstinent showed improve-
ment on these outcomes.
No differences in baseline characteristics were found
between the group who remained abstinent for 16 months
TABLE 4. Baseline characteristics of continuously abstinent (CA)
and relapsing patients (R)
CA R P
Male (%) 87.7 80.2 .198
Age 35.6 (6.4) 35.9 (6.4) .710
Health perception
EuroQol-5D
Index .75 (.24) .74 (.23) .719
VAS 70.2 (17.9) 68.1 (17.7) .431
Health perception
SF-36
General health 59.3 (19.3) 56.8 (20.4) .382
EuropASI Severity
scores (0–9)
Physical health .88 (1.4) 1.3 (1.5) .089
Work, education,
income
2.1 (2.2) 2.3 (2.3) .547
Alcohol .73 (1.4) .92 (1.7) .448
Drugs 6.3 (1.0) 6.2 (1.1) .703
Justice=police 1.2 (1.8) 1.7 (1.9) .100
Family=social relations 2.7 (1.9) 2.7 (1.8) .914
Psych=emotional
problems
2.0 (1.8) 2.1 (2.0) .567
Gambling .15 (.79) .10 (.44) .675
Craving
VAS 19.4 (23.9) 24.0 (27.3) .243
Mental health SCL-90
Agoraphobia 9.4 (4.4) 9.9 (3.4) .461
Anxiety 16.3 (6.9) 16.3 (6.6) .989
Depression 33.1 (13.5) 31.6 (11.9) .398
Somatization 20.2 (7.4) 31.6 (11.9) .782
Insufficiency 16.6 (6.2) 16.4 (6.2) .823
Interpersonal
sensitivity
29.7 (12.3) 28.8 (10.4) .571
Hostility 9.2 (3.6) 8.8 (3.4) .372
Insomnia 7.0 (3.6) 6.8 (3.5) .613
Psychotism 13.6 (4.7) 13.4 (4.5) .765
Total score 155.0 (54.3) 150.9 (48.0) .554
Regular drug use (years)
Heroin 11.5 (.4) 12.2 (6.0) .442
Methadone 6.6 (5.4) 7.7 (5.8) .221
Age at first heroin use 21.1 (5.5) 20.8 (5.0) .643
Age at first
methadone use
24.2 (8.6) 24.1 (6.7) .887
Number of previous
detoxifications
7.1 (9.1) 8.1 (7.6) .370
Substances used in the
past 30 days (ASI)
Alcohol 5.7 (10.3) 6.4 (10.3) .639
Heroin 17.5 (12.4) 18.7 (12.0) .525
Methadone 23.1 (11.1) 22.8 (10.9) .809
Cocaine 3.6 (6.3) 4.3 (7.7) .537
Cannabis 7.5 (11.7) 7.5 (11.5) .982
>1 substance 15.6 (11.8) 18.9 (11.8) .060
(Continued)
TABLE 4. Continued
CA R P
Employment (%)
Fully employed 53.2 49.2
Part-time employed 14.5 9.6
Unemployed 32.3 41.1 .344
Marital status (%)
Single 71.0 69.7
Married 16.1 13.6
Divorced=widowed 12.9 16.7 .726
Education (%)
Lower 77.4 68.7
Secondary 19.4 20.7
Higher 3.2 10.6 .177
Note. Figures are means, standard deviations, and percentages.
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and those who relapsed. No significant predictors for
continued abstinence were found among the large number
of characteristics included in the study. Hence, a relative
large subgroup of opioid-dependent patients was able to
achieve sustained abstinence. Consequently, abstinence
as a goal of treatment is attainable for a larger proportion
of opioid-dependent patients than has been assumed to
date. We would conclude that a relatively large group
of patients who are motivated for an abstinence-oriented
approach may benefit from the comprehensive series of
interventions described in this article.
LIMITATIONS
The design chosen for the add-on effect of general
anesthesia in the rapid induction of withdrawal was that
of a randomized controlled trial. This was followed by a
naturalistic design with a non-randomized evaluation
as a major limitation, even though it was performed
following recent guidelines for such studies.34 The study
aimed to follow detoxified opioid-dependent patients over
a follow-up period of 16 months. This meant that no
conclusions could be drawn concerning the causal rela-
tionship between the combination of naltrexone and
CRA and abstinence in opioid-dependent patients, nor
for the differential effect of CRA or naltrexone.
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